Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ImmunoBiome Inc. logo — ImmunoBiome aims to develop microbiome therapeutics to treat...

ImmunoBiome Inc.

ImmunoBiome aims to develop microbiome therapeutics to treat incurable diseases like cancer and autoimmune diseases

Founded 2019 Korea South Korea South 24 employees Series B Total: $27.23M Biotechnology

General Information

Company Name ImmunoBiome Inc.
Founded Year 2019
Location Korea South Korea South +2
Employees 24
Industries Biotechnology
Funding Stage Series B
Social

Get notified when ImmunoBiome Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ImmunoBiome Inc.

ImmunoBiome Inc. is a biotechnology startup based in South Korea, founded in 2019. The company's core technology revolves around developing microbiome therapeutics to combat incurable diseases such as cancer and autoimmune diseases. Their Avatiome™ is being hailed as the Next Generation Immunophenotyping System set to revolutionize immune disease treatment. In their latest funding round, ImmunoBiome secured an impressive $18.00M in Series B investment on 23 September 2021, with backing from a consortium of esteemed investors including Aju IB Investment, DSC Investment, KTB Network, Korea Investment & Securities, Korean Investment Partners, and CJ CheilJedang Corp. With the backing of such notable investors and the promise of groundbreaking technology, ImmunoBiome is positioned to make significant strides in the field of microbiome-targeted therapeutics.

Taxonomy: microbiome therapeutics, immune diseases, cancer treatment, autoimmune diseases, Avatiome, immunophenotyping, innovation, immunotherapy, medical research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		23 Sep 2021
Series A •••••• 3
Investor Investor Investor
23 Sep 2020
Seed Round •••••• 1
Investor
09 Nov 2019

ImmunoBiome Inc. Alternatives & Competitors

ImmunoBiome Inc. vs
INGENIA Therapeutics
INGENIA Therapeutics United States

INGENIA Therapeutics strives to develop antibodies to treat multiple diseases including cancer & inf...

14 employees
ImmunoBiome Inc. vs
SCYNEXIS, Inc.
SCYNEXIS, Inc. United States

Advancing innovative solutions for severe rare diseases

Unknown
49 employees
Biotechnology
ImmunoBiome Inc. vs
Antlia Bioscience, Inc.
Antlia Bioscience, Inc. United States

Turning promising peptides into groundbreaking therapeutics for chronic diseases

4 employees
Biotechnology, Health Care
Compare ImmunoBiome Inc. vs Antlia Bioscience, Inc.

FAQ About ImmunoBiome Inc.

ImmunoBiome aims to develop microbiome therapeutics to treat incurable diseases like cancer and autoimmune diseases
ImmunoBiome Inc. was founded in 2019.
ImmunoBiome Inc. is headquartered in Korea South.
ImmunoBiome Inc. operates in the following industries: Biotechnology.
ImmunoBiome Inc. has approximately 24 employees.
ImmunoBiome Inc. has completed 3 funding rounds, raising a total of $27.23M. The latest funding stage is Series B.
Top alternatives and competitors to ImmunoBiome Inc. include INGENIA Therapeutics, SCYNEXIS, Inc., Antlia Bioscience, Inc., ProGeLife, AltruBio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmunoBiome Inc. and INGENIA Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ImmunoBiome Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy